AcellaCare Salisbury
Welcome,         Profile    Billing    Logout  
 8 Trials 
17 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Oral, Elif A
NCT04026178: Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy

Active, not recruiting
4
10
US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalized Lipodystrophy
10/24
04/25
APG-20 OLE, NCT06679270: Open-label Extension Study to Evaluate Metreleptin in Patients with Partial Lipodystrophy

Recruiting
3
15
US
Metreleptin
Amryt Pharma
Familial Partial Lipodystrophy
03/28
03/28
NCT05351164: Evaluation of Safety and Efficiency of Metreleptin Treatment for Patients With Multiple Symmetric Lipomatosis (MSL)

Active, not recruiting
2
4
US
Metreleptin
University of Michigan, Amryt Pharma
Lipomatosis, Multiple Symmetrical
04/24
04/25
LEAP, NCT05088460: A Study to Examine the Effects of the Leptin Receptor (LEPR) Agonist Antibody REGN4461 in Adult Patients With Familial Partial Lipodystrophy (FPLD)

Terminated
2
20
Europe, US, RoW
REGN4461, mibavademab, Matching Placebo
Regeneron Pharmaceuticals
Familial Partial Lipodystrophy, Metabolic Abnormalities
12/23
04/24
NCT02404896: Expanded Access Metreleptin Study

Available
N/A
US
Metreleptin, MyaLept
University of Michigan
Familial Partial Lipodystrophy
 
 
STEP-1, NCT04101669: RESET System Pivotal Trial (Rev F)

Recruiting
N/A
264
US
RESET Liner, RESET Sleeve, Duodenal-jejunal Bypass Liner (DJBL), EndoBarrier, Sham
Morphic Medical Inc., Biostatistical Consulting, Inc.
Diabetes type2, Obesity
12/25
12/26
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
NCT03087253: The LD Lync Study - Natural History Study of Lipodystrophy Syndromes

Recruiting
N/A
500
US, RoW
University of Michigan
Lipodystrophy (Genetic or Acquired, Non HIV)
03/31
03/31
MEASuRE, NCT02325674: Metreleptin Effectiveness And Safety Registry

Recruiting
N/A
100
Europe, US
Metreleptin
Aegerion Pharmaceuticals, Inc.
Generalised Lipodystrophy, Partial Lipodystrophy
10/31
10/31
RADIANT, NCT05544266: Rare and Atypical Diabetes Network

Recruiting
N/A
2000
US
University of South Florida, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Diabetes Mellitus Progression, Glucose Intolerance, Glucose Metabolism Disorders, Metabolic Disease, Endocrine; Complications, Endocrine System Diseases
09/30
09/30
Patrick, Vanessa
STTEPP, NCT05603702: Safety, Tolerability and Dose Limiting Toxicity of Lacosamide in Patients With Painful Chronic Pancreatitis

Recruiting
1
24
US
Lacosamide, VIMPAT
Indiana University, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Chronic Pain, Chronic Pain Syndrome, Chronic Pancreatitis, Hyperalgesia, Opioid Use Disorder, Opioid-Related Disorders, Opioid Dependence, Chronic Abdominal Pain, ERCP, Pancreatic Surgery
03/25
03/25
NCT04158297: ESWL Versus SOPIL for Treatment of Pancreatic Duct Stones

Active, not recruiting
N/A
60
US
ESWL vs SOPIL
Indiana University
Chronic Pancreatitis, Pancreatic Duct Stone
12/25
12/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Powell, Talessa
ACHIEVE-4, NCT05803421: A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk

Active, not recruiting
3
2749
Europe, US, RoW
Orforglipron, LY3502970, Insulin Glargine
Eli Lilly and Company
Type 2 Diabetes, Obesity, Overweight or Obesity, Overweight, Cardiovascular Diseases, Chronic Kidney Disease
09/25
01/26
ACHIEVE-3, NCT06045221: A Study of Orforglipron (LY3502970) Compared With Semaglutide in Participants With Type 2 Diabetes Inadequately Controlled With Metformin

Active, not recruiting
3
1576
Japan, US, RoW
Orforglipron, LY3502970, Semaglutide
Eli Lilly and Company
Type 2 Diabetes
09/25
09/25
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26
Stonebreaker, Spring
REVITA-T2Di, NCT04419779: Evaluation of the Efficacy and Safety of DMR Using the Revita® in Subjects With Inadequately Controlled Type 2 Diabetes

Recruiting
N/A
320
Europe, US
Duodenal Mucosal Resurfacing (DMR), Duodenal Mucosal Resurfacing (Sham)
Fractyl Health Inc.
Type 2 Diabetes
06/25
01/26

Download Options